Drugmaker Odyssey Therapeutics aims to raise $238.3 million in US IPO

ReutersMay 4, 2026 10:34 AM

View all comments（0）



May 4 (Reuters) - Biopharmaceutical company Odyssey Therapeutics said on Monday it was targeting to raise as much as $238.3 million in its initial public offering in the United States.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

Anthropic in Talks for Massive $30 Billion Funding, Valuation May Join Trillion-Dollar Ranks

TradingKey - On May 12, Eastern Time, Bloomberg reported that AI startup Anthropic is in preliminary discussions with investors to raise at least $30 billion in new capital at a pre-money valuation exceeding $900 billion. If the deal is finalized, it would mark the company's largest funding round to

Asia-Pacific Stocks Hover Near Highs; Kospi Hits Record Closing High; Samsung to Face Longest-Ever Strike.

Tradingkey - Markets continue to monitor details of the meeting between the U.S. and Chinese heads of state, with major Asia-Pacific equity markets hovering at high levels. U.S. inflation rose to 3.8% in April, a nearly three-year high, weighing on U.S. chip stocks. Samsung may face the longest strike in its history, which pressured Japanese and South Korean stocks in early trading before they fluctuated upward to close higher. U.S. President Trump is scheduled to arrive in Beijing on Wednesday evening. According to sources close to the matter, the summit will discuss Iran, artificial intelligence, nuclear weapons, and rare earths. The business delegation for this visit spans technology, finance, aviation, and agriculture, including Tesla (TSLA) CEO Elon Musk, Apple (AAPL) CEO Tim Cook, and executives from semiconductor firms such as Qualcomm (QCOM) and Micron (MU). The aviation sector includes Boeing (BA) CEO Kelly Ortberg, while the financial sector includes Citigroup (C), Goldman Sachs (GS), and Blackstone Group (

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

TradingKey - Cerebras Systems (CBRS) IPO prices May 13–14 at $125–$135/share. $26–$27B valuation, 20x oversubscribed, $510M revenue, 47% net margin, OpenAI 750MW deal. Everything you need to know.

Palantir Stock Forecast: Is a Trillion-Dollar Market Cap for PLTR Stock Achievable by 2030?

Whether Palantir reaches the trillion-dollar level will depend on whether it can maintain its technological lead and successfully make the transition from a U.S.-centered powerhouse to a global AI utility.

AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

TradingKey - On May 5 (ET), Advanced Micro Devices (AMD) released its first-quarter fiscal 2026 financial results after the market close. The company reported revenue of $10.253 billion, up 38% year-over-year, exceeding market expectations of $9.89 billion. Non-GAAP earnings per share (EPS) were $1.

Featured Tools